BFM
BCTXL

Boothbay Fund Management’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

Boothbay Fund Management’s Portfolio BCTXL Stock Details BCTXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,000
Closed -$83.8K – 2757
2026
Q1 		$83.8K Buy
+20,000
New +$21.2K ﹤0.01% 1888

Other funds holding BCTXL

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Boothbay Fund Management's BCTXL Position: Q2 2026 in Review

Boothbay Fund Management sold out of BriaCell Therapeutics Warrant (BCTXL) in Q2 2026, closing a stake of 20,000 shares — an estimated $83.8K sold.

Boothbay Fund Management first reported a position in BCTXL in Q1 2026 and held it in 1 quarter. The position peaked at $83.8K in Q1 2026. 10 funds tracked by Wall St. Rank hold BCTXL as of Q2 2026.

  • Boothbay Fund Management reported no remaining BriaCell Therapeutics Warrant position as of Q2 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 20,000 BriaCell Therapeutics Warrant shares in Q2 2026, an estimated $83.8K.
  • Boothbay Fund Management first reported a position in BriaCell Therapeutics Warrant in Q1 2026 and held it in 1 quarter.
  • Boothbay Fund Management's BriaCell Therapeutics Warrant position peaked at $83.8K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.